Fate Therapeutics stocks heads for record selloff after Janssen collaboration terminated and job cuts

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 48 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 22%
  • Publisher: 97%

Business News News

Business Business Latest News,Business Business Headlines

Shares of Fate Therapeutics Inc. plunged 56.8% in premarket trading, putting them on track for a record one-day selloff, after the biopharmaceutical company...

Shares of Fate Therapeutics Inc.

plunged 56.8% in premarket trading, putting them on track for a record one-day selloff, after the biopharmaceutical company announced the termination of its collaboration with Janssen Biotech Inc. and announced job cuts. The company said it had declined Janssen’s proposal to continue the collaboration on “revised terms and conditions.” The company added that it was cutting its workforce to about 220 employees, which compares with a workforce of 279 as of Dec.

plunged 56.8% in premarket trading, putting them on track for a record one-day selloff, after the biopharmaceutical company announced the termination of its collaboration with Janssen Biotech Inc. and announced job cuts. The company said it had declined Janssen’s proposal to continue the collaboration on “revised terms and conditions.” The company added that it was cutting its workforce to about 220 employees, which compares with a workforce of 279 as of Dec.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in BUSİNESS

Business Business Latest News, Business Business Headlines